These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 28467330)
81. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. Tursi A; Papa A; Danese S Aliment Pharmacol Ther; 2015 Sep; 42(6):664-84. PubMed ID: 26202723 [TBL] [Abstract][Full Text] [Related]
82. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Majewski M; Reddymasu SC; Sostarich S; Foran P; McCallum RW Am J Med Sci; 2007 May; 333(5):266-70. PubMed ID: 17505166 [TBL] [Abstract][Full Text] [Related]
83. Faecal retention: a common cause in functional bowel disorders, appendicitis and haemorrhoids--with medical and surgical therapy. Raahave D Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748875 [TBL] [Abstract][Full Text] [Related]
84. Rifaximin: new therapeutic indication and future directions. Rivkin A; Gim S Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091 [TBL] [Abstract][Full Text] [Related]
85. [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders]. Gasztonyi B; Hunyady B Orv Hetil; 2004 Oct; 145(43):2177-81. PubMed ID: 15575494 [TBL] [Abstract][Full Text] [Related]
86. Rifaximin in the management of colonic diverticular disease. Latella G; Scarpignato C Expert Rev Gastroenterol Hepatol; 2009 Dec; 3(6):585-98. PubMed ID: 19929580 [TBL] [Abstract][Full Text] [Related]
87. Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical Trials. Picchio M; Elisei W; Brandimarte G; Di Mario F; Malfertheiner P; Scarpignato C; Tursi A J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S64-9. PubMed ID: 27622370 [TBL] [Abstract][Full Text] [Related]
90. Interaction between rifaximin and dietary fibre in patients with diverticular disease. D'Incà R; Pomerri F; Vettorato MG; Dal Pont E; Di Leo V; Ferronato A; Medici V; Sturniolo GC Aliment Pharmacol Ther; 2007 Apr; 25(7):771-9. PubMed ID: 17373915 [TBL] [Abstract][Full Text] [Related]
91. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Pimentel M Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924 [TBL] [Abstract][Full Text] [Related]
92. Faecal calprotectin in colonic diverticular disease: a case-control study. Tursi A; Brandimarte G; Elisei W; Giorgetti GM; Inchingolo CD; Aiello F Int J Colorectal Dis; 2009 Jan; 24(1):49-55. PubMed ID: 18941760 [TBL] [Abstract][Full Text] [Related]
93. Mesalazine and rifaximin in symptomatic uncomplicated diverticular disease. Festi D; Colecchia A Am J Gastroenterol; 2009 Feb; 104(2):532. PubMed ID: 19174809 [No Abstract] [Full Text] [Related]
96. Patients with Diverticular Disease Have Different Dietary Habits Compared to Control Subjects: Results from an Observational Italian Study. Polese B; Carabotti M; Rurgo S; Ritieni C; Sarnelli G; Barbara G; Pace F; Cuomo R; Annibale B; Nutrients; 2023 Apr; 15(9):. PubMed ID: 37432301 [TBL] [Abstract][Full Text] [Related]
97. Clinical features of symptomatic uncomplicated diverticular disease: a multicenter Italian survey. Annibale B; Lahner E; Maconi G; Usai P; Marchi S; Bassotti G; Barbara G; Cuomo R Int J Colorectal Dis; 2012 Sep; 27(9):1151-9. PubMed ID: 22573184 [TBL] [Abstract][Full Text] [Related]